The global epilepsy devices market size was valued at USD 1,760 million in 2022. It is estimated to reach USD 3,893 million by 2031, growing at a CAGR of 9.22% during the forecast period (2023–2031).
In epilepsy, aberrant brain activity results in seizures or episodes of strange behavior, sensations, and occasionally loss of awareness. Epilepsy is a central nervous system (neurological) illness. Epilepsy is one of the most prominent neurological conditions, affecting around 50 million people worldwide, according to the WHO. The term "epilepsy devices" refers to a few devices that can detect and lower the frequency of seizures. In addition, vagus nerve stimulation (VNS), responsive neurostimulation (RNS), and deep brain stimulation (DBS) are the only three methods of seizure frequency reduction that have received FDA approval.
|Market Size||USD 3,893 million by 2031|
|Fastest Growing Market||Europe|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
According to studies, older persons have a higher risk of developing epilepsy. Older adults are more likely to develop epilepsy as a result of neurological conditions, including stroke and Alzheimer's, as well as a higher risk of head injuries from falls and brain tumors, according to the National Center for Chronic Disease Prevention and Health Promotion in the US. A further report from the Centers for Disease Control and Prevention (CDC), US, in August 2020 stated that 3 million people in the US suffer from epilepsy, with 1 million individuals being 55 years of age or older. As a result, the market is expanding as epilepsy is becoming more common in elderly persons.
Moreover, according to the UN, the population aged 65 years had grown from 6% in 1990 to 9% in 2019. It is projected that this population will account for 16% of the population by 2050. Furthermore, about 727 million individuals aged 65 years or over were living in 2020, which is projected to increase to approximately 1.5 billion in 2050. Thus, a rise in the aging population is likely to fuel the demand for the epilepsy devices market as the senior population is more prone to epilepsy.
One of the most frequent triggers for the beginning of epilepsy is a head injury or brain damage; falls, car accidents, and incidents at construction sites are some of the most frequent sources of head injuries. According to the Epilepsy Foundation of America, in July 2020, 10% of the people who suffer a Traumatic Brain Injury (TBI) suffered from an early seizure. These seizures are mostly found to be of the tonic-clonic type. For instance, according to CDC, about 61,000 TBI-related deaths were recorded in 2019 in the US. Furthermore, according to The Brown Firm (US), in February 2021, car accidents accounted as the second leading cause of TBI, after falls, i.e., about 35% of all TBI cases. Therefore, due to the high rates of road accidents leading to brain injuries, the demand for epilepsy devices will also increase.
Epilepsy is a persistent brain condition that can affect people of any age. In June 2019, it affected more than 50 million people globally, according to WHO. They added that over 80% of people suffering from epilepsy reside in low- and middle-income nations. In such counties, almost 75% of epilepsy patients do not receive the necessary epilepsy diagnosis, monitoring, or medication. Unfortunately, many of these low- and middle-income nations lack access to adequate healthcare infrastructure and, as a result, do not have access to epilepsy devices. This is limiting the market's growth because a sizable portion of those who might have been potential end users are unable to access the market.
It is projected that rising regions like Asia-Pacific will drive market expansion. As of June 2019, over 80% of people living with epilepsy lived in low- and middle-income countries, according to the WHO. The Royal Melbourne Hospital in Australia also estimates that nearly half of the world's epilepsy prevalence—or around 23 million—occurs in Asia. Furthermore, stroke and road accidents—the common causes of epilepsy—are also very high in these regions. For instance, China accounts for the highest number of stroke cases in the world, with 354 cases per 100,000 people in 2016, according to a report published in The Lancet Journal in March 2019. In addition, according to WHO, in June 2021, around 93% of road accident-related deaths worldwide happened in low- and middle-income countries. Therefore, there is a huge demand and need for epilepsy devices in the regions. With new R&D efforts to make epilepsy devices that are cost-effective and cater to the needs of these emerging markets, this stands as a viable opportunity for future market growth.
By Region, the global epilepsy devices market is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Americas is the most significant shareholder in the global epilepsy devices market and is anticipated to grow at a CAGR of 9.50% during the forecast period. A developed healthcare infrastructure, supportive governmental policies, the presence of the regional headquarters of significant key firms like Boston Scientific Corporation and Empatica, Inc., and an increase in epilepsy patients drive the regional market. For instance, in May 2019, Healthline Media (US) reported that 1.2% of the US population, or over 3.4 million people, have active epilepsy. One in 26 Americans receives an epilepsy diagnosis at some point in their lifetime. Additionally, epilepsy is the fourth most prevalent neurological ailment, behind migraine, stroke, and Alzheimer's disease in the US. The major firms in the area are also investing a lot in R&D to create new items and receive product approvals. For instance, the Neuronaute EEG System and IceCap EEG wearable device, which allow for remote monitoring of epilepsy patients, were approved by the FDA in February 2021 by BioSerenity, Inc. (France). In February 2018, Empatica Inc. (US) received FDA approval for the Embrace smartwatch, which monitors seizures, especially the generalized tonic-clonic seizure.
Europe is expected to grow at a CAGR of 8.0% over the forecast period. The availability of reimbursement, an increasing senior population susceptible to epilepsy, and technological improvements in treatment devices all predict that the European market for epilepsy devices will expand during the projected period. Furthermore, the presence of highly developed healthcare infrastructure and research funds from governmental organizations are expected to have a positive impact on the European epilepsy devices market. The elderly population in the EU-27 is anticipated to grow from 90.5 million in 2019 to 129.8 million by 2050, according to Eurostat. In addition, older people have a higher risk of developing epilepsy. Hence the market for epilepsy gadgets is being driven by the expanding senior population. Further, important regional companies are receiving product approvals, which will also increase the demand. For instance, in April 2018, LovaNova (UK) got the CE mark approval for its Vagus Nerve Stimulation Therapy system called the SenTiva generator.
The epilepsy device market in Asia-Pacific is expanding at the fastest rate among all regions because of its rapid growth and the appearance of several players. The high frequency of epilepsy in the area fuels market expansion. Nearly 80% of people living with epilepsy, according to the WHO, reside in low- and middle-income nations as of June 2019. In addition, a study by the Royal Melbourne Hospital in Australia found that 23 million of the 4 billion individuals who call Asia home—roughly 50% of the world's population—have epilepsy. Furthermore, the region's high presence of the older population is also driving the market. According to a report by Seoul National University Hospital, South Korea, in June 2019, epilepsy was the third most common neurological disorder after stroke and dementia in older adults. Also, according to Population Reference Bureau, in 2019, Japan had the highest percentage of the older (above 65 years old) population globally, i.e., 28% of the people in 2019. Therefore, the demand for epilepsy devices is high.
The Middle East and African epilepsy devices market is expected to expand slowly due to poor consumer awareness and low affordability. However, rising public health awareness and government initiatives to bring cutting-edge technologies to the region are credited with driving market expansion in the Middle East and Africa. The region also has a high prevalence of epilepsy, which is not adequately treated. Epilepsy is the second most prevalent neurological condition after stroke, according to a survey from the University of Washington in the US. The developed gulf countries drive a significant portion of the growth in this region. Furthermore, R&D efforts into developing effective epilepsy devices in the region are also helping the market grow. For instance, in September 2020, researchers at Ben-Gurion University, Israel, developed a novel wearable device for epilepsy prediction called Epiness. The device used machine learning to predict seizures and notify the patient through an app about an hour before the stroke.
The global epilepsy devices market is divided into wearable devices, conventional devices, implantable devices, and diet.
The conventional devices segment is the highest contributor to the market and is expected to grow at a CAGR of 7.73% during the forecast period. Conventional devices refer to electroencephalogram (EEG) devices used for the continuous monitoring of patients. According to WHO, the best indicators of seizure recurrence include thorough etiology documentation and an abnormal EEG pattern. As a result, there is a massive market for EEG devices that monitor epileptic patients. The widespread use of traditional EEG equipment in hospitals and clinics, the increasing need for epilepsy surveillance in clinical trials, and the availability of reimbursement for EEG treatments in developed nations contribute to the segment's rise in demand.
The global epilepsy devices market is divided into Vagus Nerve Stimulation, responsive neurostimulation, Deep Brain Stimulation (DBS), and accelerometry.
The Vagus Nerve Stimulation segment is responsible for the highest market share and is estimated to grow at a CAGR of 6.83% over the forecast period. An FDA-approved treatment for adults and kids with refractory epilepsy or medication-resistant epilepsy is vagus nerve stimulation. It is a technique for neuromodulation that uses the vagus nerve to deliver gentle electrical pulses to the brain. The VNS devices are placed under the skin in the left chest area. According to a study of 65 patients published by the Epilepsy Foundation of America in March 2018, seizures decreased after the use of VNS by 36% in 6 months, 58% in 4 years, and 70% in 10 years. In another study conducted by Seoul National University, South Korea, in May 2019, VNS reduced seizures by more than half in about 60% of patients; this rate increased as the follow-up period lengthened. VNS has a 3–6% complication rate, with infection being the most concerning issue.
The global epilepsy devices market is divided into electroencephalogram (EEG), intracranial EEG, surface electromyography (sEMG), electrodermal activity (EDA), electrocardiography (EKG), video detection systems, implanted advisory systems and others.
The electroencephalogram (EEG) segment owns the highest market share and is estimated to grow at a CAGR of 11.78% over the forecast period. The most popular and crucial approach for finding epilepsy is the electroencephalogram. Electrodes linked to the scalp are used during the procedure, which is painless and secure. The EEG devices examine if the electrical signals from the brain are consistent with the patterns detected by these electrodes. EEG devices detect several other disorders, such as brain trauma, stroke, brain cancer, or seizures. The EEG system only collects the brain signals and does not interfere with brain activity in any way. Different types of EEGs are conducted for different scenarios for epilepsy detection, including Standard EEG tests, Sleep EEG tests, Sleep-deprived EEG tests, Ambulatory EEG tests, Video-telemetry tests, and Invasive EEG-telemetry.
The global epilepsy devices market is divided into hospitals and clinics, neurology centers, home care settings, and others.
The hospitals and clinics segment is the most significant contributor to the market and is expected to grow at a CAGR of 10.53% during the forecast period. Due to the availability of devices for treating epilepsy and patients' preference for visiting hospitals and clinics, hospitals and clinics are anticipated to increase considerably over the forecast period. Additionally, the gradual increase in the number of public and private hospitals worldwide is fueling this market's expansion. For instance, the American Hospital Association (AHA) figures from 2019 indicate that there were 6,210 hospitals in the US overall in 2017. Hence, the above factors are expected to boost the market growth of this segment during the forecast period.
January 2023- Medtronic plc has been included in the 2023 Rankings of America's Most JUST Companies by JUST Capital and media partner CNBC in recognition of its dedication to serving its employees, customers, communities, the environment, and shareholders.
December 2022- Medtronic plc announced that the HugoTM robotic-assisted surgery (RAS) system had enrolled its first patient in the Expand URO U.S. clinical study. Dr. Michael R. Abern conducted the robotic-assisted prostatectomy at Duke University Hospital in Durham, North Carolina.